Literature DB >> 28296570

Statistical design of noninferiority multiple region clinical trials to assess global and consistent treatment effects.

Guoqing Diao1, Donglin Zeng2, Joseph G Ibrahim2, Alan Rong3, Oliver Lee3, Kathy Zhang3, Qingxia Chen4.   

Abstract

Noninferiority multiregional clinical trials (MRCTs) have recently received increasing attention in drug development. While a major goal in an MRCT is to estimate the global treatment effect, it is also important to assess the consistency of treatment effects across multiple regions. In this paper, we propose an intuitive definition of consistency of noninferior treatment effects across regions under the random-effects modeling framework. Specifically, we quantify the consistency of treatment effects by the percentage of regions that meet a predefined treatment margin. This new approach enables us to achieve both goals in one modeling framework. We propose to use a signed likelihood ratio test for testing the global treatment effect and the consistency of noninferior treatment effects. In addition, we provide guidelines for the allocation rule to achieve optimal power for testing consistency among multiple regions. Extensive simulation studies are conducted to examine the performance of the proposed methodology. An application to a real data example is provided.

Entities:  

Keywords:  Consistency of treatment effects; global treatment effect; multiregional clinical trial; noninferiority clinical trial; random effects model; signed likelihood ratio test

Mesh:

Year:  2017        PMID: 28296570      PMCID: PMC5787861          DOI: 10.1080/10543406.2017.1293075

Source DB:  PubMed          Journal:  J Biopharm Stat        ISSN: 1054-3406            Impact factor:   1.051


  9 in total

1.  International Conference on Harmonisation; guidance on ethnic factors in the acceptability of foreign clinical data; availability--FDA. Notice.

Authors: 
Journal:  Fed Regist       Date:  1998-06-10

2.  Testing for interaction in studies of noninferiority.

Authors:  Brian L Wiens; Joseph F Heyse
Journal:  J Biopharm Stat       Date:  2003-02       Impact factor: 1.051

3.  Consideration of regional difference in design and analysis of multi-regional trials.

Authors:  H M James Hung; Sue-Jane Wang; Robert T O'Neill
Journal:  Pharm Stat       Date:  2010 Jul-Sep       Impact factor: 1.894

Review 4.  Assessing consistent treatment effect in a multi-regional clinical trial: a systematic review.

Authors:  Joshua Chen; Hui Quan; Bruce Binkowitz; S Peter Ouyang; Yoko Tanaka; Gang Li; Shailendra Menjoge; Ekopimo Ibia
Journal:  Pharm Stat       Date:  2010 Jul-Sep       Impact factor: 1.894

5.  Empirical shrinkage estimator for consistency assessment of treatment effects in multi-regional clinical trials.

Authors:  Hui Quan; Mingyu Li; Weichung Joe Shih; Soo Peter Ouyang; Joshua Chen; Ji Zhang; Peng-Liang Zhao
Journal:  Stat Med       Date:  2012-08-01       Impact factor: 2.373

6.  Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.

Authors:  Eric Van Cutsem; Marc Peeters; Salvatore Siena; Yves Humblet; Alain Hendlisz; Bart Neyns; Jean-Luc Canon; Jean-Luc Van Laethem; Joan Maurel; Gary Richardson; Michael Wolf; Rafael G Amado
Journal:  J Clin Oncol       Date:  2007-05-01       Impact factor: 44.544

7.  Cetuximab for the treatment of colorectal cancer.

Authors:  Derek J Jonker; Chris J O'Callaghan; Christos S Karapetis; John R Zalcberg; Dongsheng Tu; Heather-Jane Au; Scott R Berry; Marianne Krahn; Timothy Price; R John Simes; Niall C Tebbutt; Guy van Hazel; Rafal Wierzbicki; Christiane Langer; Malcolm J Moore
Journal:  N Engl J Med       Date:  2007-11-15       Impact factor: 91.245

8.  K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

Authors:  Christos S Karapetis; Shirin Khambata-Ford; Derek J Jonker; Chris J O'Callaghan; Dongsheng Tu; Niall C Tebbutt; R John Simes; Haji Chalchal; Jeremy D Shapiro; Sonia Robitaille; Timothy J Price; Lois Shepherd; Heather-Jane Au; Christiane Langer; Malcolm J Moore; John R Zalcberg
Journal:  N Engl J Med       Date:  2008-10-23       Impact factor: 91.245

9.  Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study.

Authors:  Timothy J Price; Marc Peeters; Tae Won Kim; Jin Li; Stefano Cascinu; Paul Ruff; Atilli Satya Suresh; Anne Thomas; Sergei Tjulandin; Kathy Zhang; Swaminathan Murugappan; Roger Sidhu
Journal:  Lancet Oncol       Date:  2014-04-14       Impact factor: 41.316

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.